Several studies showed a complete lack of response to treatment with an EGFR TKI [17], [21], [22], one study demonstrated that NSCLC patients with tumors harboring KRAS mutations had a similar outcome to either EGFR TKI or chemotherapy [3]. Here, KRAS is linked to non-small cell lung carcinoma.